Drug Database · Clinicians

Flucloxacillin

Also known as: floxacillin (US name)

Brands (7) Coxafen, Fluclox, Stafloxin…Show all

Antibacterial (penicillin-beta-lactamase combination); Antibacterial (beta-lactamase resistant penicillin); and others PH FDA category

CrCl <10: max 1 g every 8–12 hRx · Prescription drug11 PH products Kidney dosing reviewed
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
US label not yet available for this generic. Check the Philippine package insert (linked in the products table where the FDA has published one).

Contraindications

  • Beta-lactam (penicillin, cephalosporin) hypersensitivity
  • Previous flucloxacillin-associated jaundice or hepatic dysfunction
renalcarematters.com, reviewed

Dosing: Adult

  • Staphylococcal infections (oral, adults and children over 10): 250 to 500 mg three times daily, 1 hour before or 2 hours after food
  • Osteomyelitis, endocarditis: Up to 8 g/day in divided doses every 6 to 8 hours
  • Surgical prophylaxis: 1 to 2 g intravenously at induction, then 500 mg every 6 hours for up to 72 hours
renalcarematters.com, reviewed

Dosing: Altered kidney function

Flucloxacillin is partly excreted in urine (20% to 50% of an oral dose) and is not removed by hemodialysis. The Irish label usually needs no dose reduction in kidney impairment; below creatinine clearance (CrCl) 10 mL/min it advises a lower dose or longer interval, with high-dose regimens capped at 1 g every 8 to 12 hours. It has no US FDA label.

Kidney function measure: Irish summary of product characteristics (SmPC) uses creatinine clearance (CrCl, mL/min); single threshold at 10 mL/min.

Show full dosing details
CrCl ≥60 mL/min
Usual: 250 to 500 mg orally three times daily; up to 8 g/day in divided doses every 6 to 8 hours for osteomyelitis or endocarditis (SmPC).
CrCl 30–59 mL/min
No dose reduction usually needed (SmPC).
CrCl 15–29 mL/min
No dose reduction usually needed at CrCl ≥10 (SmPC). Watch for neurotoxicity with high intravenous doses.
CrCl <15 mL/min (not on dialysis)
CrCl 10–14: no change. CrCl <10: reduce the dose or extend the interval; with high-dose regimens give no more than 1 g every 8 to 12 hours (SmPC).
Hemodialysis (intermittent)
Dose as for CrCl <10 (high-dose regimens maximum 1 g every 8 to 12 hours). Not significantly removed by hemodialysis; no supplementary dose needed (SmPC).
Peritoneal dialysis
No PD-specific data; dose as for CrCl <10 (maximum 1 g every 8 to 12 hours for high-dose regimens).
CRRT
No data in the SmPC. Specialist input.
  • Dialyzable? No: not significantly removed by hemodialysis (SmPC).
  • Monitoring Liver and kidney function during prolonged courses (cholestatic jaundice, hepatitis). High anion gap metabolic acidosis with paracetamol, especially in severe kidney impairment or sepsis; check urinary 5-oxoproline if suspected. Potassium (hypokalemia at high doses). Sodium load about 51 mg per gram (SmPC 4.4).
Children (kidney dosing)
Show full dosing details
eGFR ≥60
Normal kidney function: usual age-based doses (SmPC).
eGFR 30–59
No pediatric-specific kidney data; adult rule (no change unless CrCl <10) is a reasonable guide.
eGFR 15–29
No pediatric-specific kidney data; adult rule (no change unless CrCl <10) is a reasonable guide.
eGFR <15 (not on dialysis)
No pediatric-specific kidney data; adult rule: reduce dose or extend interval.
Hemodialysis (intermittent)
No pediatric data; specialist input.
Peritoneal dialysis
No pediatric data; specialist input.
CRRT
No pediatric data; specialist input.

Pediatric eGFR: bedside Schwartz equation, 0.413 × height (cm) / serum creatinine (mg/dL). Weight-based doses should not exceed the adult maximum.

renalcarematters.com guidance, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Sources are listed under References. Use with the product's package insert and the patient's current kidney function.

Source: HPRA (Ireland) product information (May 2023). This generic has no US FDA label.

Dosing: Pediatric

Approved ages
All ages, including newborns with caution (SmPC).
Usual dose
Over 10 years: adult dose. 2 to 10 years: half the adult dose. Under 2 years: one-quarter of the adult dose (SmPC).

Newborns: caution (hyperbilirubinemia, kernicterus, reduced renal excretion).

Kidney dosing in children: see Dosing: Altered kidney function.

renalcarematters.com, reviewed

Dosage forms

Philippines

  • Capsule: 250 mg, 500 mg

Registered products in the Philippines

11 products registered with the Food and Drug Administration (FDA) Philippines list Flucloxacillin as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

All registered products11
Philippine FDA-registered products for Flucloxacillin
Package insert
CoxafenFlucloxacillin (as Sodium)
500 mg CapsuleFoil Strip x 10's (Box of 50's)
Rx
Lloyd Laboratories, Inc.Philippines
Aldril Pharmaceuticals, Inc.Trader: Totalcare Pharma Inc.
DR-XY32914
Jan 31, 2027
CoxafenFlucloxacillin (as Sodium)
500 mg CapsuleFoil Strip x 10's (Box of 50's)
Rx
Lloyd Laboratories, Inc.Philippines
Aldril Pharmaceuticals, Inc.Trader: Totalcare Pharma Inc.
DRP-15164
Jan 31, 2027
FloxacilFlucloxacillin (as Sodium)
500 mg CapsuleBlister Pack x 10's (Box of 50's)
Rx
Drugmaker's Laboratories, Inc.Philippines
—
DRP-3964
Jun 17, 2030
FlucloxFlucloxacillin (as sodium)
500 mg Capsule
Rx
Lloyd Laboratories, Inc.
Randril International Co., Inc.
DR-XY32639
Nov 17, 2026Past listed date
FlucloxFlucloxacillin (as sodium)
500 mg CapsuleFoil Strip x 10's (Box of 50's)
Rx
Lloyd Laboratories, Inc.Philippines
Randril International Co., Inc.
DRP-15048
Nov 17, 2026Past listed date
FlusaphcloxFlucloxacillin
500 mg CapsuleAluminum Foil Strip Pack x 10's (Box of 50's and 100's)
Rx
Sapphire Lifesciences Pvt. Ltd.China
Ollen Pharma Trading, Inc.
DRP-13022
Nov 17, 2027
KhrizfloxinFlucloxacillin
500 mg CapsuleAlu-PVDC Blister Pack x 10's (Box of 100's) FB
Rx
Sparsh Bio-Tech Pvt. Ltd.India
Khriz Pharma Trading Inc.
DR-XY49100
May 31, 2029
LucloxFlucloxacillin (as sodium)
500 mg CapsuleStrip Foil x 10's (Box of 100's)
Rx
Lloyd Laboratories, Inc.Philippines
Trader: Westfield Pharmaceuticals, Inc.
DRP-10392
Feb 14, 2027
StafloxinFlucloxacillin (as sodium)
250 mg CapsuleFlex Foil x 10's (Box of 50's)
Rx
Asian Antibiotics, Inc.Philippines
Trader: UNILAB, Inc
DR-XY16012
Feb 8, 2031
StafloxinFlucloxacillin (as sodium)
500 mg CapsuleFlex Foil x 10's (Box of 50's)
Rx
Asian Antibiotics, Inc.Philippines
Trader: UNILAB, Inc
DR-XY16013
Feb 8, 2031
UnbrandedFlucloxacillin (as sodium)
500 mg CapsuleAlu/Poly foil strip x 10's (Box of 50's)
Rx
Lloyd Laboratories, Inc.Philippines
—
DRP-10756
Nov 16, 2031

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

Drug interactions

Drug or classSeverityEffectWhat to do
Paracetamol (acetaminophen)Adjust or monitorHigh anion gap metabolic acidosis (5-oxoproline), mainly with severe kidney impairment, sepsis or malnutrition.Use with caution; monitor acid–base status.
VoriconazoleAdjust or monitorVoriconazole levels fall markedly.Monitor voriconazole levels; dose increase may be needed.
ProbenecidMinorSlower flucloxacillin excretion.Usually no action.
Bacteriostatic antibioticsMinorMay reduce bactericidal effect.Avoid unnecessary combination.

Severity scale (renalcarematters.com): Avoid: do not combine; Adjust or monitor: change the dose or monitor closely; Minor: usually no action.

renalcarematters.com, reviewed

Adverse reactions

Common

  • Nausea, diarrhea

Serious

  • Cholestatic jaundice and hepatitis (may be delayed up to 2 months after stopping; most fatal cases in people over 50 or with serious underlying disease)
  • Anaphylaxis
  • Stevens-Johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis
  • Interstitial nephritis
  • Neutropenia, agranulocytosis
  • Convulsions with high intravenous doses in kidney failure
  • Clostridioides difficile colitis
  • Hypokalemia; high anion gap metabolic acidosis with paracetamol
renalcarematters.com, reviewed

Monitoring parameters

  • Liver and kidney function during prolonged courses (cholestatic jaundice, hepatitis). High anion gap metabolic acidosis with paracetamol, especially in severe kidney impairment or sepsis; check urinary 5-oxoproline if suspected. Potassium (hypokalemia at high doses). Sodium load about 51 mg per gram (SmPC 4.4). Kidney
  • Liver tests in long courses and if jaundice appears; never re-challenge after flucloxacillin jaundice; kidney function in long courses
  • Potassium at high doses
  • Acid–base status if combined with paracetamol in at-risk patients
renalcarematters.com, reviewed

Pharmacokinetics

Key PK parameters

BioavailabilityWell absorbed; absorption halved when taken with food
Half-life40 to 45 minutes
Half-life in kidney failure (ESKD) kidneyNot stated in SmPC
Protein binding90% to 95%
Renal excretion kidney20% to 50% of an oral dose in urine
Dialyzability kidneyNo (not significantly removed by hemodialysis)
renalcarematters.com, reviewed

Formulary and pricing (Philippines)

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. Health Products Regulatory Authority (Ireland). Flucillin capsules 500 mg SmPC (PA0281/031/005) [HPRA (Ireland) product information, May 2023; no US FDA label]. https://assets.hpra.ie/products/Human/16336/Licence_PA0281-031-005_29052023122944.pdf
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
  3. Pinewood Laboratories Ltd. (2023). Flucillin (flucloxacillin) capsules 500 mg [Summary of product characteristics, licence PA0281/031/005; text revised May 2023]. Health Products Regulatory Authority (Ireland). https://assets.hpra.ie/products/Human/16336/Licence_PA0281-031-005_29052023122944.pdf

renalcarematters.com content: Kidney and pediatric dosing: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Dosing, interaction, adverse-effect and monitoring summary: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .